{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:53:49Z","timestamp":1785038029806,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40120-022-00432-x","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T16:02:56Z","timestamp":1677254576000},"page":"635-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-2932","authenticated-orcid":false,"given":"Marco","family":"Capobianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"deFiebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lana-Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hong","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M.","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"432_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/460825","volume":"2012","author":"J Oh","year":"2012","unstructured":"Oh J, Levy M. Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int. 2012;2012: 460825.","journal-title":"Neurol Res Int"},{"issue":"9","key":"432_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493\u2013506.","journal-title":"Nat Rev Neurol"},{"issue":"9451","key":"432_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et\u00a0al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106\u201312.","journal-title":"Lancet"},{"issue":"6","key":"432_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","volume":"23","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23(6):661\u201383.","journal-title":"Brain Pathol"},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jns.2016.06.030","volume":"368","author":"JM Seok","year":"2016","unstructured":"Seok JM, Cho EB, Lee HL, Cho HJ, Min JH, Lee KH, et\u00a0al. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2016;368:209\u201313.","journal-title":"J Neurol Sci"},{"issue":"2","key":"432_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et\u00a0al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"4","key":"432_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","volume":"92","author":"BG Weinshenker","year":"2017","unstructured":"Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92(4):663\u201379.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"432_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.msard.2015.07.015","volume":"4","author":"K Mutch","year":"2015","unstructured":"Mutch K, Zhao S, Hamid S, Methley A, Elsone L, Singh G, et\u00a0al. Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2015;4(6):614\u20138.","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"432_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/00207454.2011.608456","volume":"121","author":"D He","year":"2011","unstructured":"He D, Chen X, Zhao D, Zhou H. Cognitive function, depression, fatigue, and activities of daily living in patients with neuromyelitis optica after acute relapse. Int J Neurosci. 2011;121(12):677\u201383.","journal-title":"Int J Neurosci"},{"issue":"7","key":"432_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","volume":"77","author":"Y Kanamori","year":"2011","unstructured":"Kanamori Y, Nakashima I, Takai Y, Nishiyama S, Kuroda H, Takahashi T, et\u00a0al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011;77(7):652\u20138.","journal-title":"Neurology"},{"key":"432_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","volume":"17","author":"S Eaneff","year":"2017","unstructured":"Eaneff S, Wang V, Hanger M, Levy M, Mealy MA, Brandt AU, et\u00a0al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116\u201322.","journal-title":"Mult Scler Relat Disord"},{"key":"432_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","volume":"293","author":"Z Shi","year":"2016","unstructured":"Shi Z, Chen H, Lian Z, Liu J, Feng H, Zhou H. Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression. J Neuroimmunol. 2016;293:54\u20138.","journal-title":"J Neuroimmunol"},{"issue":"9","key":"432_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"13","key":"432_CR14","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3109\/09638288.2013.833301","volume":"36","author":"K Mutch","year":"2014","unstructured":"Mutch K, Methley A, Moore P, Jacob A. Life on hold: the experience of living with neuromyelitis optica. Disabil Rehabil. 2014;36(13):1100\u20137.","journal-title":"Disabil Rehabil"},{"issue":"1","key":"432_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hex.12432","volume":"20","author":"AM Methley","year":"2017","unstructured":"Methley AM, Mutch K, Moore P, Jacob A. Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study. Health Expect. 2017;20(1):47\u201358.","journal-title":"Health Expect"},{"issue":"5","key":"432_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000269","volume":"3","author":"RA Kessler","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3(5): e269.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"432_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","volume":"21","author":"MA Mealy","year":"2019","unstructured":"Mealy MA, Boscoe A, Caro J, Levy M. Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. Int J MS Care. 2019;21(3):129\u201334.","journal-title":"Int J MS Care"},{"issue":"5","key":"432_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53(5):1107\u201314.","journal-title":"Neurology"},{"issue":"1","key":"432_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","volume":"18","author":"RA Kessler","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol. 2016;18(1):2.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"432_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/WNO.0000000000000102","volume":"34","author":"MC Kowarik","year":"2014","unstructured":"Kowarik MC, Soltys J, Bennett JL. The treatment of neuromyelitis optica. J Neuroophthalmol. 2014;34(1):70\u201382.","journal-title":"J Neuroophthalmol"},{"key":"432_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00431-y","author":"J-H KowaMinrik","year":"2023","unstructured":"Min J-H, Capobianco M, Welsh C, et al. Understanding treatment decisions in neuromyelitis optica spectrum disorder: a global clinical record review with patient interviews. Neurol Ther. 2023. https:\/\/doi.org\/10.1007\/s40120-022-00431-y.","journal-title":"Neurol Ther"},{"issue":"8","key":"432_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellner","year":"2010","unstructured":"Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et\u00a0al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019\u201332.","journal-title":"Eur J Neurol"},{"issue":"24","key":"432_CR23","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","volume":"77","author":"TF Scott","year":"2011","unstructured":"Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128\u201334.","journal-title":"Neurology"},{"issue":"1","key":"432_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et\u00a0al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1\u201316.","journal-title":"J Neurol"},{"issue":"4","key":"432_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, et\u00a0al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180\u20137.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"432_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et\u00a0al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"432_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et\u00a0al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"key":"432_CR28","unstructured":"FDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal Cord [press release]. 2020."},{"key":"432_CR29","unstructured":"FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord [press release]. 2020."},{"issue":"22","key":"432_CR30","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et\u00a0al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114\u201324.","journal-title":"N Engl J Med"},{"issue":"10206","key":"432_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et\u00a0al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"22","key":"432_CR32","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","volume":"91","author":"SH Kim","year":"2018","unstructured":"Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et\u00a0al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089\u201399.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00432-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:32:38Z","timestamp":1679916758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00432-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00432-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}